Repligen (RGEN) fundamentals: P/E, valuation, undervalued?
Repligen · Health Care · ref. ETF XLV · price $182.03
In short — Repligen trades at 252.8× earnings (P/E), 69.0× forward, with a net margin of 5.3 % and revenue growth of +12 %. Read: Very expensive vs its growth (P/E 69 very high vs ~12% growth (PEG 5.8)).
Is Repligen stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$182.03+49.0% over range
Aug 28, 25low $102.87 · high $182.03Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
89% recommend buying · 9 analysts
Valuation : Very expensive vs its growth — P/E 69 very high vs ~12% growth (PEG 5.8)
Valuation
252.8
P/E (price/earnings)
69.0
Forward P/E
—
PEG
4.9
Price/book (P/B)
$10.3B
Market cap
0.72
EPS
Profitability & growth
5.3 %
Net margin
+12 %
Revenue growth
-66 %
Earnings growth
$691M
Total debt
Repligen income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $802M | $186M | 23.2 % |
| 2023 | $639M | $42M | 6.5 % |
| 2024 | $634M | $-26M | -4.0 % |
| 2025 | $738M | $49M | 6.6 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Repligen's P/E and is the stock undervalued? What's a good P/E?
Repligen's P/E is 252.8 (forward 69.0). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Very expensive vs its growth".
Is Repligen profitable?
Repligen has a net margin of 5.3 % (EPS 0.72). The company is profitable.
Is RGEN stock expensive?
Our read: "Very expensive vs its growth" — P/E 69 very high vs ~12% growth (PEG 5.8). Cross-check with growth and sector.
💬 A question about Repligen? The JPI assistant answers using our backtest data.
Keep exploring Repligen